HDAC9 and cancer: Other drug treatments that alter HOXA9-associated gene expression signature were found among the tested cell lines (Supplementary Figure 3H), including several anti-cancer drugs, particularly histone deacetylase (HDAC) inhibitors trichostatin A (TSA), vorinostat and MS-275 [21], which are able to promote cell cycle arrest and apoptosis [22], and tanespimycin and its analogues geldanamycin, alvespimycin, and monorden [23, 24], which are HSP90 inhibitors also currently tested as anti-cancer drugs.